Brief: European Commission Approves Commercialisation of RYEQO for Symptomatic Treatment of Endometriosis
02/11/2023 13:29
Nov 2 (Reuters) - Sumitomo Pharma Co Ltd 4506.T :
* SUMITOMO PHARMA AMERICA - EUROPEAN COMMISSION APPROVES
COMMERCIALISATION OF RYEQO FOR SYMPTOMATIC TREATMENT OF
ENDOMETRIOSIS
* SUMITOMO PHARMA AMERICA - EUROPEAN COMMISSION DECISION
FOLLOWED
POSITIVE CHMP OPINION AND IS APPLICABLE FOR ALL MEMBER STATES IN
EUROPEAN UNION
Source text for Eikon: ID:nPn9p71mba
Further company coverage: 4506.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)